Table 2 Drugs that were found to be significant (raw p < 0.05) out of clinical trial candidates available for survival analysis
Drug name | Hazard ratios | Raw P value | Lower CI | Upper CI | Total matched pairs | Drug users with AD | Non-users with AD | Trial | Drug description |
|---|---|---|---|---|---|---|---|---|---|
Clinical trial candidates with low hazard ratios | |||||||||
Valacyclovir | 0.560 | 4.72E − 03 | 0.37 | 0.84 | 8519 | 37 | 66 | Phase II | Antiviral |
Montelukast | 0.617 | 1.39E − 02 | 0.42 | 0.91 | 7254 | 42 | 68 | Phase II | Inflammation |
Losartan | 0.727 | 3.24E − 02 | 0.54 | 0.97 | 13,399 | 78 | 107 | Phase III | Diabetes |
Clinical trial candidates with high hazard ratios | |||||||||
Escitalopram | 3.258 | 2.08E − 05 | 1.89 | 5.61 | 3830 | 55 | 17 | Phase III, phase I | Anxiety |
Mirtazapine | 3.105 | 2.31E − 04 | 1.70 | 5.68 | 1544 | 43 | 14 | Phase III | Depression |
Levetiracetam | 4.034 | 5.28E − 03 | 1.51 | 10.75 | 877 | 20 | 5 | Phase III, phase II, European | Seizures |
Levodopa | 3.435 | 1.53E − 02 | 1.27 | 9.31 | 727 | 17 | 5 | European | Parkinson’s |
Eszopiclone | 3.009 | 3.29E − 02 | 1.09 | 8.28 | 1033 | 15 | 5 | Phase III | Insomnia |